Nuclear Molecular Imaging of Disease Burden and Response to Treatment for Cardiac Amyloidosis

Cardiac amyloidosis (CA) is a heterogeneous group of diseases in which extracellular insoluble amyloid proteins are deposited in specific organs and tissues locally or systemically, thereby interfering with physiological function. Transthyretin protein (TTR) and light chain (AL) amyloidosis are the...

Full description

Bibliographic Details
Main Authors: Min Zhao, Raffaella Calabretta, Josef Yu, Patrick Binder, Shuo Hu, Marcus Hacker, Xiang Li
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Biology
Subjects:
Online Access:https://www.mdpi.com/2079-7737/11/10/1395
Description
Summary:Cardiac amyloidosis (CA) is a heterogeneous group of diseases in which extracellular insoluble amyloid proteins are deposited in specific organs and tissues locally or systemically, thereby interfering with physiological function. Transthyretin protein (TTR) and light chain (AL) amyloidosis are the most common types of cardiac amyloidosis. Radionuclide bone scintigraphy has recently become the most common non-invasive test for the diagnosis of TTR-CA but is of limited value for the diagnosis of AL-CA. PET has proved promising for the diagnosis of CA and its applications are expected to expand in the future. This review summarizes the current bone scintigraphy and amyloid-targeting Positron emission tomography (PET) imaging, the binding imaging properties of radiotracers, and the values of diagnosis, prognosis, and monitoring therapy response in CA.
ISSN:2079-7737